IDiyas

For the Inventor, By the Inventor

San Mateo, CA, United States of America

Jing Wu

USPTO Granted Patents = 32 

 

Average Co-Inventor Count = 10.8

ph-index = 7

Forward Citations = 145(Granted Patents)


Location History:

  • Santa Clara, CA (US) (2001)
  • San Mateo, CA (US) (2000 - 2005)
  • San Meteo, CA (US) (2006)
  • Redwood City, CA (US) (2008 - 2010)

Company Filing History:

goldMedal7 out of 202 
 
Elan Pharmaceuticals, Inc.
 patents
silverMedal7 out of 4,442 
 
Eli Lilly and Company
 patents
bronzeMedal5 out of 35 
 
Athena Neurosciences, Inc.
 patents
4. 20 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2000-2010

Loading Chart...
Loading Chart...
32 patents (USPTO):Explore Patents
1. 7759382 - Acylated amino acid amidyl pyrazoles and related compounds (2010-07-20),
2. 7754712 - Bridged N-cyclic sulfonamido inhibitors of gamma secretase (2010-07-13),
3. 7432379 - [object Object] (2008-10-07),
4. 7417152 - [object Object] (2008-08-26),
5. 7345056 - Bridged N-cyclic sulfonamido inhibitors of gamma secretase (2008-03-18),
6. 7153847 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2006-12-26),
7. 6951854 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2005-10-04),
8. 6888022 - Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis (2005-05-03),
9. 6861558 - Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis (2005-03-01),
10. 6767918 - N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2004-07-27),
11. 6683075 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use (2004-01-27),
12. 6667305 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-12-23),
13. 6653303 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-11-25),
14. 6642261 - N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-11-04),
15. 6635632 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-10-21),

Certainly! Here is the article about inventor Jing Wu:

Title: Innovator Spotlight: Jing Wu

Introduction:

Jing Wu, a renowned inventor based in San Mateo, CA, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents and inventions. With a total of 32 patents to his name, Wu's innovative work has paved the way for advancements in treating neurological disorders, particularly Alzheimer's disease.

Latest Patents:

1. Acylated Amino Acid Amidyl Pyrazoles and Related Compounds:

Wu's invention of acylated amino acid amidyl pyrazoles and related compounds has revolutionized the approach to inhibiting β-amyloid peptide release and synthesis, as well as γ-secretase activity. These compounds, formulated into pharmaceutical compositions, hold promise in the prevention and treatment of Alzheimer's disease.

2. Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase:

Wu's development of N-cyclic sulfonamido compounds and salts has shown efficacy in treating and preventing cognitive disorders, including Alzheimer's Disease. The pharmaceutical compositions based on these compounds offer new avenues for addressing cognitive impairments associated with neurodegenerative conditions.

Career Highlights:

Throughout his career, Jing Wu has made significant strides in the pharmaceutical industry. Having worked at reputable companies such as Elan Pharmaceuticals, Inc., and contributed to various research projects, Wu has established himself as a pioneering figure in the field of neurological therapeutics.

Collaborations:

Wu's collaborative efforts with esteemed colleagues Lee H. Latimer and Jeffrey S. Nissen have been instrumental in advancing the research and development of innovative pharmaceutical solutions. Together, they have synergized their expertise to drive forward the discovery of novel treatments for cognitive disorders.

Conclusion:

Inventor Jing Wu's relentless pursuit of innovation and his relentless dedication to improving the lives of individuals affected by neurological disorders have cemented his legacy in the field of pharmaceuticals. His patents and inventions stand as a testament to his unwavering commitment to pushing the boundaries of scientific exploration and creating impactful solutions for addressing pressing medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…